ID - 310
SEQUOIA 5-YEAR FOLLOW-UP IN ARM C: FRONTLINE ZANUBRUTINIB MONOTHERAPY IN PATIENTS WITH DEL(17P) AND TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
R Dalfeora, CS Tamb, P Ghiac,d, M Shadmane,f, T Munirg, SS Opath, PA Walkeri, T Tianj, J Hirataj, JR Brownk
a Centro de Tratamento Oncológico (CENTRON), Américas Oncologia, Rio de Janeiro, Brazil
b Alfred Hospital and Monash University, Melbourne, Australia
c Università Vita-Salute San Raffaele, Milano, Italy
d Comprehensive Cancer Center, IRCCS Ospedale San Raffaele, Milano, Italy
e Fred Hutchinson Cancer Center, Seattle, United States
f University of Washington, Seattle, United States
g Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
h Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
i Peninsula Health and Peninsula Private Hospital, Langwarrin, Australia
j BeOne Medicines Ltd, Cambridge, United States
k Dana-Farber Cancer Institute, Boston, United States
Ver más
